The Cancer Drug Development Forum (CDDF) will hold a live webinar on “Bayesian Approaches in Oncology Drug Development: Introduction and Motivations” on 14 May at 17:00 CET. This webinar will include two lectures by Purvi Prajapati (Eli Lilly) and Natasha Mulhemann (Cytel). The lectures will be followed by a 25-minute panel discussion moderated by Eva Skovlund (CDDF) and Axel Glasmacher (CDDF).
WEBINAR OUTLINE
Bayesian methods are increasingly used in clinical development, including oncology drug development. Bayesian methods offer more intuitive interpretation due to direct estimation of the probability of the treatment effect and allow for the incorporation of prior knowledge.
The webinar “Bayesian Approaches in Oncology Drug Development: Introduction and Motivations” will focus on key Bayesian concepts and terminology without the underlying mathematics to help the audience to interpret the publications on Bayesian trials in medical literature. The speakers will discuss motivation / rationale for the use of Bayesian trials and illustrate them with examples.
Agenda: (CET time zone)
17:00 – 17:05 Introduction – Axel Glasmacher (CDDF) and Eva Skovlund (CDDF)
17:05 – 17:20 Lecture by Purvi Prajapati (Eli Lilly)
17:20 – 17:35 Lecture by Natasha Mulhemann (Cytel)
17:35 – 18:00 Panel discussion – moderated by Axel Glasmacher (CDDF) and Eva Skovlund (CDDF)
Purvi Prajapati
Purvi earned her PhD from Baylor University before joining Eli Lilly & Company in 2020. As a member of the Clinical Design Team at Lilly, she collaborates with multiple study teams to design clinical trials across all phases of drug development across the immunology therapeutic area. In addition to her role at Eli Lilly, Purvi serves as a co-chair for the Medical Outreach working group, a sub-team of the Bayesian Scientific Working Group. Her research interests span innovative clinical trials, Bayesian methodology, and Bayesian network meta-analysis methods.
Natasha Mulhemann
Natalia (Natasha) Muehlemann has over 20 years of experience in Life Sciences across several therapeutic areas, including intensive care, oncology, neurology, cardiovascular and metabolic diseases, and combines medical, statistics & data science and strategic expertise enhancing value through evidence generation, advanced analytics and stakeholders’ engagement. Natalia joined Cytel as VP, Strategic Consulting at Cytel, in 2020. At Cytel she is focusing on the integration of innovative adaptive frequentists, Bayesian designs, Machine Learning methods and RWE into comprehensive clinical development strategies that combine clinical, regulatory, market access and financial considerations. Prior to Cytel, Natalia was Global Category Head, Acute Care – Oncology – Devices at Nestle Health Sciences. Natalia acted as Expert Jury member for European Commission’s Innovation Council and SMEs Executive Agency and other Investors forums. Natalia holds MD and MBA (IMD), Certifications in medical statistics (Stanford), data science (IBM), AI/ML (MIT) and executive education in Digital Transformation in Healthcare (HMS).